arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Cabaletta Bio, Inc.

CABA
$2.49 ▲ +0.04 (+1.43%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
35 Visible periods
19 Metrics
Peer-ranked Benchmarks
Price Chart
17
Health
Poor
Bearish
auto_awesome

Analytical Summary

Cabaletta Bio, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $376.4M
Dividend Yield
Revenue Growth
Op. Margin
ROIC -19.5%
FCF / Share $-0.27
Trailing P/E
Price / Book 1.8x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 22, 2026.

35-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-43.52M
↓ -21.1%
FCF / Share Free cash flow per share
$-0.27
↑ +44.4%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
5
Financial Health
14
Cash Quality
53

Dividend History

Dividend / share · sourced from SEC filings
$0.00 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 9 years · 35 quarters